Quince Therapeutics (QNCX) Net Income (2018 - 2026)

Quince Therapeutics has reported Net Income for 9 years, with the latest figure at -$75.5 million in Q2 2026.

• On a quarterly basis, Net Income fell 370.52% year-over-year to -$75.5 million in Q2 2026; TTM through Jun 2026 was -$72.3 million, a 47.38% decrease from a year earlier, with the FY2025 full-year figure at -$63.8 million, down 12.19% from the prior year.
• Net Income was -$75.5 million for Q2 2026 at Quince Therapeutics, down from $35.9 million in the prior quarter.
• The five-year high for Net Income was $35.9 million in Q1 2026, with the low at -$75.5 million in Q2 2026.
• Average Net Income over 5 years is -$13.5 million, with a median of -$12.4 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Net Income tumbled 467.52% in 2024, then soared 338.94% in 2026.
• Over 5 years, Net Income stood at -$5.5 million in 2022, then slumped by 60.72% to -$8.9 million in 2023, then slumped by 40.58% to -$12.5 million in 2024, then slumped by 54.23% to -$19.3 million in 2025, then slumped by 291.6% to -$75.5 million in 2026.
• The last three Net Income figures came in at -$75.5 million (Q2 2026), $35.9 million (Q1 2026), and -$19.3 million (Q4 2025), per Business Quant data.